anti-MAGE-A4/HLA-A*02:01 TCR T-cell therapy (2seventy Bio)

N/A

Report date: 2025/01/26 17:02:11

Base Information

Drug Nameanti-MAGE-A4/HLA-A*02:01 TCR T-cell therapy (2seventy Bio)
Drug Alias Name27T-62
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionMelanoma-associated antigen 4 modulatorsHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators
TargetsMelanoma-associated antigen 4HLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMacauHong Kong +[4] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator Companies2seventy Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesJw Therapeutics (Shanghai) Co LtdRegeneron Pharmaceuticals Inc
Inactive Companies2seventy Bio Inc
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A